DBV Technologies SA – (NASDAQ:DBVT) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Monday.

According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “

Other analysts also recently issued research reports about the stock. Societe Generale raised shares of DBV Technologies SA – from a “hold” rating to a “buy” rating in a research report on Thursday. Jefferies Group LLC reissued a “buy” rating and set a $47.00 target price on shares of DBV Technologies SA – in a research report on Thursday. Leerink Swann reissued an “outperform” rating on shares of DBV Technologies SA – in a research report on Wednesday, March 15th. Finally, Natixis raised shares of DBV Technologies SA – from a “neutral” rating to a “buy” rating in a research report on Friday, February 17th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $46.50.

Analyst Recommendations for DBV Technologies SA - (NASDAQ:DBVT)

Shares of DBV Technologies SA – (NASDAQ:DBVT) traded up 1.55% during mid-day trading on Monday, hitting $35.42. 103,040 shares of the stock traded hands. The stock has a 50-day moving average of $35.33 and a 200 day moving average of $35.61. The stock’s market cap is $1.63 billion. DBV Technologies SA – has a one year low of $27.02 and a one year high of $37.98.

Your IP Address:

A number of hedge funds have recently modified their holdings of the stock. Royal Bank of Canada increased its stake in shares of DBV Technologies SA – by 115.8% in the second quarter. Royal Bank of Canada now owns 4,100 shares of the company’s stock valued at $133,000 after buying an additional 2,200 shares during the period. TD Asset Management Inc. purchased a new stake in shares of DBV Technologies SA – during the third quarter valued at about $272,000. TimesSquare Capital Management LLC increased its stake in shares of DBV Technologies SA – by 0.6% in the third quarter. TimesSquare Capital Management LLC now owns 990,503 shares of the company’s stock valued at $35,985,000 after buying an additional 5,950 shares during the period. Sectoral Asset Management Inc purchased a new stake in shares of DBV Technologies SA – during the third quarter valued at about $1,428,000. Finally, Sphera Funds Management LTD. increased its stake in shares of DBV Technologies SA – by 30.4% in the third quarter. Sphera Funds Management LTD. now owns 79,058 shares of the company’s stock valued at $2,872,000 after buying an additional 18,447 shares during the period. 48.96% of the stock is owned by institutional investors.

About DBV Technologies SA –

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

5 Day Chart for NASDAQ:DBVT

Get a free copy of the Zacks research report on DBV Technologies SA – (DBVT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for DBV Technologies SA - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies SA - and related companies with MarketBeat.com's FREE daily email newsletter.